Kiniksa Pharma: Up after FDA approves heart inflammation treatment

Kiniksa Pharmaceuticals International

19/03/2021 10:14

** Shares of drug developer  KNSA.O  rise 8% to $23.48
premarket
    ** U.S. FDA, on Thursday, approved co's treatment of
recurrent pericarditis, a condition characterized by relapsing
inflammation of the thin tissue sac surrounding the heart
causing sharp chest pain (https://bit.ly/3eTdc7W)
    ** Commercial launch for rilonacept, which is administered
as a weekly injection, is expected in 2021
    ** About 40,000 patients seek treatment for recurrent
pericarditis each year in U.S. - KNSA
    ** Rilonacept was discovered by Regeneron Pharmaceuticals,
Inc  REGN.O  and approved for treatment of cryopyrin-associated
periodic syndromes in 2008; KNSA licensed rilonacept from
Regeneron in 2017
    ** KNSA stock up ~23% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))